Table 5.
Characteristics of HFpEF and non-HF patients in the validation group
| Variable | HFpEF (n = 37) | non-HF (n = 302) | P |
|---|---|---|---|
| Female (n (%)) | 25(68%) | 147(49%) | 0.036 |
| Age (year) | 68 ± 2 | 62 ± 1 | 0.013 |
| HR (beats/min) | 75 ± 2 | 70 ± 1 | 0.150 |
| BMI (kg/m2) | 24.4 ± 0.7 | 24.1 ± 0.2 | 0.828 |
| Hypertension | 29(78%) | 169(56%) | 0.012 |
| CAD | 9(24%) | 68(22%) | 0.836 |
| CKD(stage ≥ 3)or ESRD | 8(22%) | 16(5%) | 0.002 |
| COPD | 1(3%) | 7(2%) | 1.000 |
| Diabetes | 10(27%) | 60(20%) | 0.291 |
| Mitral E (cm/s) | 96 ± 4 | 77 ± 1 | < 0.001 |
| Mitral A (cm/s) | 82 ± 6 | 87 ± 1 | 0.249 |
| E/A ratio | 0.9(0.8—2.0) | 0.9(0.7—1.1) | 0.014 |
| Septal e′ velocity (cm/s) | 5.0 ± 0.2 | 6.6 ± 0.1 | < 0.001 |
| Lateral e′ velocity (cm/s) | 6.0(5.0—8) | 9.0(7.0—11.0) | < 0.001 |
| E/e’ ratio | 16.2(14.1—16.2) | 9.9(7.4—14.6) | < 0.001 |
| TR peak velocity (m/s) | 2.8(2.7—3.0) | 2.5(2.3—2.7) | < 0.001 |
| LVEF (%) | 60 ± 1 | 65 ± 1 | 0.001 |
| LAVimax (ml/m2) | 42.8 ± 2.0 | 31.2 ± 0.7 | < 0.001 |
| LAEF (%) | 45 ± 3 | 55 ± 1 | < 0.001 |
| LASr(%) | 18.0 ± 1.5 | 28 ± 1 | < 0.001 |
| E/LASr ratio | 4.8(3.2—9.1) | 2.6(2.0—3.6) | < 0.001 |